Bioneutra Global Stock Revenue

BGACF Stock  USD 0.07  0.00  0.00%   
BioNeutra Global fundamentals help investors to digest information that contributes to BioNeutra Global's financial success or failures. It also enables traders to predict the movement of BioNeutra Pink Sheet. The fundamental analysis module provides a way to measure BioNeutra Global's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioNeutra Global pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

BioNeutra Global Company Revenue Analysis

BioNeutra Global's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Revenue

 = 

Money Received

-

Discounts and Returns

More About Revenue | All Equity Analysis

Current BioNeutra Global Revenue

    
  15.4 M  
Most of BioNeutra Global's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioNeutra Global is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Competition

Based on the latest financial disclosure, BioNeutra Global reported 15.4 M of revenue. This is 99.9% lower than that of the Consumer Defensive sector and 99.81% lower than that of the Packaged Foods industry. The revenue for all United States stocks is 99.84% higher than that of the company.

BioNeutra Revenue Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioNeutra Global's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of BioNeutra Global could also be used in its relative valuation, which is a method of valuing BioNeutra Global by comparing valuation metrics of similar companies.
BioNeutra Global is currently under evaluation in revenue category among its peers.

BioNeutra Fundamentals

About BioNeutra Global Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze BioNeutra Global's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioNeutra Global using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioNeutra Global based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in BioNeutra Pink Sheet

BioNeutra Global financial ratios help investors to determine whether BioNeutra Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioNeutra with respect to the benefits of owning BioNeutra Global security.